An executive at U.S. pharmaceutical company Eli Lilly reportedly identified the sleep sector as the company’s next target, following the success of its obesity drug Mounjaro. Nikkei Business reports that the interview has drawn attention to the company’s future development plans.
Following the major success of the company’s obesity drugs, including Mounjaro, Eli Lilly is reportedly considering drug development in the sleep sector as its next strategic priority.
The executive reportedly indicated that the market for sleep disorders is large and could become a long-term growth driver.
The article outlines the rationale behind the company’s strategic shift and the future direction of its research and development in the sleep sector.